Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
暂无分享,去创建一个
R. Giugliano | E. Braunwald | C. Cannon | S. Murphy | E. Bohula | S. Guneri | Jeong-Gun Park | M. Blazing | Eri Toda Kato | Jennifer A. White
[1] R. Giugliano,et al. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. , 2017, Journal of the American College of Cardiology.
[2] Marc P. Bonaca,et al. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction , 2016, Circulation.
[3] Harlan M Krumholz,et al. Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association , 2016, Circulation.
[4] R. Giugliano,et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. , 2016, Journal of the American College of Cardiology.
[5] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .
[6] Barry J. Davis,et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.
[7] R. Califf,et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.
[8] Cholesterol Treatment Trialists. Effi cacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015 .
[9] R. Herings,et al. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010. , 2013, European heart journal.
[10] Tatjana Rundek,et al. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. , 2012, Archives of internal medicine.
[11] Jerry Q. Cheng,et al. Meta-analysis of statin effects in women versus men. , 2012, Journal of the American College of Cardiology.
[12] Arlene S Bierman,et al. Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. , 2012, American heart journal.
[13] C. Cannon,et al. Benefit of Intensive Statin Therapy in Women: Results From PROVE IT-TIMI 22 , 2011, Circulation. Cardiovascular quality and outcomes.
[14] I. Palacios,et al. Sex Differences in Medical Care and Early Death After Acute Myocardial Infarction , 2008, Circulation.
[15] R. Califf,et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. , 2008, American heart journal.
[16] J. Zbilut,et al. Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins. , 2008, Gender medicine.
[17] J. Manson,et al. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2005, The New England journal of medicine.
[18] L. Newby,et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/Ameri , 2005, Journal of the American College of Cardiology.
[19] G. Anderson. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. , 2005, Journal of women's health.
[20] P. Sager,et al. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. , 2004, Journal of women's health.
[21] M. Pfeffer,et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. , 1998, Journal of the American College of Cardiology.
[22] O. Faergeman,et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) , 1997, Circulation.